Established in 2001, Domainex is a privately owned, rapidly growing drug research company with expertise in expression of disease target proteins, hit discovery, hit-to-lead identification and lead optimisation.
It has an established reputation for its high quality, innovative approach and has a sustained track record of delivering preclinical drug candidates. Domainex has a wide range of UK and international clients including biotechnology and pharmaceutical companies, and several leading academic groups.
To facilitate expansion across all aspects of its drug research service business, including the biology, analytical and medicinal chemistry departments, Domainex signed a long-term lease with Aviva Investors in October 2015 to provide it with the facilities and infrastructure required to support the company’s growth. Following a period of refurbishment, Domainex transitioned into its new facility, the Churchill Building, in August.
The existing 20,000 sq ft building has been refurbished to meet Domainex’s immediate and future requirements for chemistry and biology laboratory space. Works included the addition of a new laboratory access corridor, new windows throughout and a reorganization of the internal layouts plus the addition of a new reception lobby.
The external aesthetics of the building were also enhanced via the recladding of the roof. The building gives Domainex more than a two-fold increase in laboratory space, allowing the company to start to recruit the additional experienced and ambitious medicinal chemists, assay biologists, analytical chemists and protein scientists required to fuel its continued growth.
Trevor Perrior, Chief Scientific Officer of Domainex, commented of the move: “The Domainex service business has been growing rapidly for several years, and it was obvious that we needed to find new premises that would allow scope for that expansion to continue, and also provide a first-class working environment for our team. Our new laboratories at Chesterford are exactly what we were looking for, and have given us the space we need to expand across all departments. We anticipate that the high-quality of our new building and the excellent on-site facilities will help us to attract the new staff we now want to recruit.”
Chesterford Research Park provides an innovative, flexible and future-proofed environment for both established and early stage biotechnology and pharmaceutical research and development companies. Domainex joins successful organisations such as AstraZeneca, Illumina Inc. and Charles River Laboratories, who have also chosen Chesterford as the base from which to advance their specific science.
The low-density development, set within 250 acres of impressive parkland, offers ultra-modern and energy efficient laboratory and office space as well as central ‘hub’ facilities within The Nucleus building, which includes a restaurant, café bar, health and fitness centre, and meeting and conferencing space.
Accommodation options at Chesterford range from managed office space and individual R&D suites to bespoke build prelets, giving occupiers multiple options as their requirements change and grow.